Table 5. . Threshold analysis of the list price for rivaroxaban with and without generic pricing assumption: cost–effectiveness analysis results comparing apixaban switchers (to rivaroxaban) versus apixaban continuers.
| Discount to rivaroxaban list price | Generic pricing enabled† | Generic pricing excluded | ||||
|---|---|---|---|---|---|---|
| Incremental cost | Incremental QALYs | Cost per QALY | Incremental cost | Incremental QALYs | Cost per QALY | |
| 0% | €4967.76 | -0.079 | Dominated | €8577.10 | -0.079 | Dominated |
| 10% | €4863.54 | Dominated | €7534.90 | Dominated | ||
| 20% | €4759.32 | Dominated | €6492.69 | Dominated | ||
| 30% | €4655.10 | Dominated | €5450.48 | Dominated | ||
| 40% | €4550.87 | Dominated | €4408.27 | Dominated | ||
| 50% | €4446.65 | Dominated | €3366.06 | Dominated | ||
| 60% | €4342.43 | Dominated | €2323.85 | Dominated | ||
| 70% | €4238.21 | Dominated | €1281.64 | Dominated | ||
| 80% | €4133.99 | Dominated | €239.43 | Dominated | ||
| 90% | €4029.77 | Dominated | -€802.78 | €10,152.08 (not cost-effective) | ||
| 100% | €3925.55 | Dominated | -€1844.99 | €23,332.05 (not cost-effective) | ||
†
For the purpose of this threshold analysis, incremental discounts were applied to the rivaroxaban list price prior to loss of exclusivity, meaning any further discounts due to generic pricing were applied to this discounted list price.
QALY: Quality-adjusted life year.